Effect of Folic Acid in Levodopa Treated Parkinson's Disease Patients
Status:
Recruiting
Trial end date:
2024-07-16
Target enrollment:
Participant gender:
Summary
This is a prospective single center, randomized, double-blind, 2 arm placebo-controlled study
in subjects with Parkinson's disease receiving levodopa .The patients will be randomized to
receive tablet Folic Acid 10 mg per day or placebo for 8 weeks. The safety and efficacy
outcome measures will be assessed at baseline and 8 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh